We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
Thanks to the Nagel Foundation and their generous support of NHF Idaho.
Catalyst Biosciences, Inc. recently released an update relevant to an ongoing Phase 1/2 clinical trial for CB 2679d/ISU304, the company’s investigational therapy for the treatment of patients with severe hemophilia B/factor IX (FIX) deficiency. Catalyst develops its therapies using engineered proteases, enzymes that increase the rate of chemical reactions within cells. These proteases can target the proteins associated with certain underlying diseases and conditions, such as FIX.
Because of their lower factor levels, hemophilia patients are generally thought to be better protected from cardiovascular disease (CVD). To determine whether data would support this long-held assumption, a team of investigators enrolled patients from 19 U.S. hemophilia treatment centers (HTCs) in the “CVD in Hemophilia” study. The lead author of the study was Barbara Konkle, MD, Professor of Medicine in the Division of Hematology at the University of Washington School of Medicine in Seattle, WA.
Investigators looked into whether having hemophilia protected patients against cardiovascular disease.
Grifols Announces Recall of One Lot of Profilnine. This recall is being conducted as a precautionary measure.
Subscribe to Our Newsletter
Fill in the fields below to receive our email newsletter.